Cargando…
Distribution in Rat Blood and Brain of TDMQ20, a Copper Chelator Designed as a Drug-Candidate for Alzheimer’s Disease
(1) Background: TDMQ20 is a specific regulator of copper homeostasis in the brain, able to inhibit cognitive impairment in the early stages of Alzheimer’s disease (AD) in mouse models of AD. To promote the further development of this drug-candidate, preliminary data on the pharmacokinetics of TDMQ20...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785178/ https://www.ncbi.nlm.nih.gov/pubmed/36559185 http://dx.doi.org/10.3390/pharmaceutics14122691 |
_version_ | 1784857985769537536 |
---|---|
author | Huang, Lan Zeng, Yaoxun Li, Yongliang Zhu, Yingshan He, Yan Liu, Yan Robert, Anne Meunier, Bernard |
author_facet | Huang, Lan Zeng, Yaoxun Li, Yongliang Zhu, Yingshan He, Yan Liu, Yan Robert, Anne Meunier, Bernard |
author_sort | Huang, Lan |
collection | PubMed |
description | (1) Background: TDMQ20 is a specific regulator of copper homeostasis in the brain, able to inhibit cognitive impairment in the early stages of Alzheimer’s disease (AD) in mouse models of AD. To promote the further development of this drug-candidate, preliminary data on the pharmacokinetics of TDMQ20 in a mammal model have been collected. Since TDMQ20 should be administered orally, its absorption by the gastrointestinal tract was evaluated by comparison of blood concentrations after administration by oral and IV routes, and its ability to reach its target (the brain) was confirmed by comparison between blood and brain concentrations after oral administration. (2) Methods: plasmatic and brain concentrations of the drug after oral or intravenous treatment of rats at pharmacologically relevant doses were determined as a function of time. (3) Results: oral absorption of TDMQ20 was rapid and bioavailability was high (66% and 86% for males and females, respectively). The drug accumulated in the brain for several hours (brain–plasma ratio 3 h after oral administration = 2.6), and was then efficiently cleared. (4) Conclusions: these data confirm that TDMQ20 efficiently crosses the brain–blood barrier and is a relevant drug-candidate to treat AD. |
format | Online Article Text |
id | pubmed-9785178 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97851782022-12-24 Distribution in Rat Blood and Brain of TDMQ20, a Copper Chelator Designed as a Drug-Candidate for Alzheimer’s Disease Huang, Lan Zeng, Yaoxun Li, Yongliang Zhu, Yingshan He, Yan Liu, Yan Robert, Anne Meunier, Bernard Pharmaceutics Article (1) Background: TDMQ20 is a specific regulator of copper homeostasis in the brain, able to inhibit cognitive impairment in the early stages of Alzheimer’s disease (AD) in mouse models of AD. To promote the further development of this drug-candidate, preliminary data on the pharmacokinetics of TDMQ20 in a mammal model have been collected. Since TDMQ20 should be administered orally, its absorption by the gastrointestinal tract was evaluated by comparison of blood concentrations after administration by oral and IV routes, and its ability to reach its target (the brain) was confirmed by comparison between blood and brain concentrations after oral administration. (2) Methods: plasmatic and brain concentrations of the drug after oral or intravenous treatment of rats at pharmacologically relevant doses were determined as a function of time. (3) Results: oral absorption of TDMQ20 was rapid and bioavailability was high (66% and 86% for males and females, respectively). The drug accumulated in the brain for several hours (brain–plasma ratio 3 h after oral administration = 2.6), and was then efficiently cleared. (4) Conclusions: these data confirm that TDMQ20 efficiently crosses the brain–blood barrier and is a relevant drug-candidate to treat AD. MDPI 2022-12-01 /pmc/articles/PMC9785178/ /pubmed/36559185 http://dx.doi.org/10.3390/pharmaceutics14122691 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Huang, Lan Zeng, Yaoxun Li, Yongliang Zhu, Yingshan He, Yan Liu, Yan Robert, Anne Meunier, Bernard Distribution in Rat Blood and Brain of TDMQ20, a Copper Chelator Designed as a Drug-Candidate for Alzheimer’s Disease |
title | Distribution in Rat Blood and Brain of TDMQ20, a Copper Chelator Designed as a Drug-Candidate for Alzheimer’s Disease |
title_full | Distribution in Rat Blood and Brain of TDMQ20, a Copper Chelator Designed as a Drug-Candidate for Alzheimer’s Disease |
title_fullStr | Distribution in Rat Blood and Brain of TDMQ20, a Copper Chelator Designed as a Drug-Candidate for Alzheimer’s Disease |
title_full_unstemmed | Distribution in Rat Blood and Brain of TDMQ20, a Copper Chelator Designed as a Drug-Candidate for Alzheimer’s Disease |
title_short | Distribution in Rat Blood and Brain of TDMQ20, a Copper Chelator Designed as a Drug-Candidate for Alzheimer’s Disease |
title_sort | distribution in rat blood and brain of tdmq20, a copper chelator designed as a drug-candidate for alzheimer’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785178/ https://www.ncbi.nlm.nih.gov/pubmed/36559185 http://dx.doi.org/10.3390/pharmaceutics14122691 |
work_keys_str_mv | AT huanglan distributioninratbloodandbrainoftdmq20acopperchelatordesignedasadrugcandidateforalzheimersdisease AT zengyaoxun distributioninratbloodandbrainoftdmq20acopperchelatordesignedasadrugcandidateforalzheimersdisease AT liyongliang distributioninratbloodandbrainoftdmq20acopperchelatordesignedasadrugcandidateforalzheimersdisease AT zhuyingshan distributioninratbloodandbrainoftdmq20acopperchelatordesignedasadrugcandidateforalzheimersdisease AT heyan distributioninratbloodandbrainoftdmq20acopperchelatordesignedasadrugcandidateforalzheimersdisease AT liuyan distributioninratbloodandbrainoftdmq20acopperchelatordesignedasadrugcandidateforalzheimersdisease AT robertanne distributioninratbloodandbrainoftdmq20acopperchelatordesignedasadrugcandidateforalzheimersdisease AT meunierbernard distributioninratbloodandbrainoftdmq20acopperchelatordesignedasadrugcandidateforalzheimersdisease |